Placebo | Page 36 of 57 | SpiritIndia.com

Caffeine :: Caffeine cuts post-workout pain by nearly 50 percent

Although it’s too soon to recommend dropping by Starbucks before hitting the gym, a new study suggests that caffeine can help reduce the post-workout soreness that discourages some people from exercising. In a study to be published in the February issue of The Journal of Pain, a team of University of Georgia researchers finds that moderate doses of caffeine, roughly equivalent to two cups of coffee, cut post-workout muscle pain by up to 48 percent in a small sample of volunteers.

Chronic Fatigue Syndrome :: New therapy for chronic fatigue syndrome to be tested at Stanford

A preliminary study suggests there may be hope in the offing for some sufferers of chronic fatigue syndrome with a new therapy being tested by researchers at the Stanford University School of Medicine.

Is evidence-based medicine sufficient for complementary and alternative medicine research?

Evidence-based medicine is widely accepted among researchers as the “gold-standard” for scientific approaches. Over the years, EBM has both supported and denied the value of allopathic medicine practices, while having less association with complementary and alternative medicine (CAM) practices. Since most CAM practices are complex and focus on healing rather than cure the question arises as to whether EBM principles are sufficient for making clinical decisions about CAM.

Diabetes :: Benefits of Diachrome for people with type 2 diabetes

Nutrition 21, Inc., today announced the results of a recent placebo controlled, double-blind, randomized, single center study that demonstrated that Diachrome, a patented combination of chromium picolinate and biotin, safely improves blood glucose levels and cholesterol metabolism in people with type 2 diabetes.

Parkinson’s Disease :: Parkinson’s drug rotigotine shows promise

Research led by a team from UAB (University of Alabama at Birmingham) has shown that a dopamine agonist called rotigotine could be effective in treating symptoms of Parkinson?s disease (PD). In a study published Jan. 3 in the online edition of Neurology, rotigotine significantly improved symptoms in patients with early-stage PD.

Liver Cancer :: No benefit for liver cancer patients from long-acting octreotide

Long-acting octreotide does not improve outcomes for patients with liver cancer compared to a placebo, according to the results of a new double blind study published in the January 2007 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

Heart Attack :: Medication does not benefit for certain heart attack patients undergoing PCI

Use of the drug pexelizumab immediately before and for 24 hours after stent placement or angioplasty for certain heart attack patients did not have any significant treatment effect compared to placebo, according to a study in the January 3 issue of JAMA. The medication had shown promise in preliminary studies.

Pregnancy :: Prenatal multivitamins for undernourished women reduce risk of low birth weight

Undernourished women who take a vitamin and mineral supplement while pregnant may be less likely than women taking only iron and folic acid supplements to have babies weighing less than 2,500 grams, and their newborns may be less likely to have morbidity in the first seven days of life, according to a report in the January issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

Parkinson’s Disease :: Epilepsy drug levodopa improves tremors, involuntary movements in Parkinson patients

A drug used to treat epilepsy has been found to significantly improve tremors, motor fluctuations and other involuntary movements, or dyskinesias, in patients with Parkinson disease, according to a study published in the Jan. 2, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.

Hearing Loss :: Folic acid slowed hearing loss in special elderly population

In a three-year study, 728 older men and women with high blood homocysteine levels and no hearing loss were given either daily oral folic acid or a placebo supplement. Daily folic acid supplementation slowed decline in hearing of low frequencies by 0.7dB after three years.